Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data – the PULSE study

por Bellanca, Leana, Linden, Stephan, Farmer, Ruth
Publicado 2023

Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malay...

por Ong, Siew Chin, Low, Joo Zheng, Linden, Stephan
Publicado 2023

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England

por Kolovos, Spyros, Bellanca, Leana, Groyer, Harinala, Rosano, Giuseppe, Gaultney, Jennifer, Linden, Stephan
Publicado 2023

A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction

por Tafazzoli, Ali, Reifsnider, Odette S., Bellanca, Leana, Ishak, Jack, Carrasco, Marc, Rakonczai, Pal, Stargardter, Matthew, Linden, Stephan
Publicado 2022

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%

por Kolovos, Spyros, Bellanca, Leana, Groyer, Harinala, Rosano, Giuseppe M.C., Solé, Alexandra, Gaultney, Jennifer, Linden, Stephan
Publicado 2023

Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study

por Winterstein, Almut G, Gerhard, Tobias, Kubilis, Paul, Saidi, Arwa, Linden, Stephan, Crystal, Stephen, Zito, Julie, Shuster, Jonathan J, Olfson, Mark
Publicado 2012

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

por Reifsnider, Odette S., Kansal, Anuraag R., Franke, Jennifer, Lee, Joseph, George, Jyothis T., Brueckmann, Martina, Kaspers, Stefan, Brand, Sarah B., Ustyugova, Anastasia, Linden, Stephan, Stargardter, Matthew, Hau, Nikco
Publicado 2020